Mindray
迈瑞医疗
In elsewhere's corpus, Mindray (迈瑞医疗) appears primarily as the acquirer of APT Medical (惠泰医疗, a Qiming Venture Partners portfolio company) in early 2024 — a deal Qiming's William Hu was involved in throughout, and which became the STAR Market's first "A-controls-A" acquisition, widely read as a signal of a coming M&A wave in China . Beyond that transaction, the corpus contains no dedicated coverage of Mindray itself — its founding, business lines, or scale are not documented here.
AI-generated — may contain errors, please verify.
Coverage
Qiming Venture Partners' William Hu: China Is Seeing the Birth of a Wave of Global Pharmaceutical Companies
Over the next five to ten years, more highly original R&D breakthroughs are expected to emerge from labs in China and contribute to global pharmaceutical innovation.
Entrepreneurship Is the Most Hardcore Way for Young People to Change the World | Mono X Campus
Be a long-term partner to founders, not a short-term "referee."
Qiming Perspective | William Hu on the Ecosystem Logic Behind Innovative Drug M&A Integration
In this era of transformation, Qiming Venture Partners places greater emphasis on whether a company's technology and products achieve genuine breakthroughs, and whether it can deliver clinical value that others cannot. Qiming Venture Partners supports enterprises that bring tangible benefits to patients.
Exclusive | Daniel Zhang Joins Primavera Capital, Continuing His Unfettered Path in M&A
"Industry consolidators prefer winter."
VBData Exclusive | Dalton Venture: The Next Phase of Opportunities in Healthcare — "Technology + Safety" Is the Unavoidable Theme
In a turbulent environment, most investment firms have chosen to play it safe, pulling back on deal activity. Yet in 2023 — widely called a funding winter — Dalton Venture actually picked up its investment pace. How does the firm see 2024 shaping up? At the start of the new year, Sun Qi, founding and managing partner of Dalton Venture, sat down with VBData to share his outlook on healthcare trends for 2024 and his advice for founders.
"Inside Listed Companies - LEPU Medical Technology" and "Medical Device Overseas Expansion" Post-Investment Events Successfully Held!
Building a company all the way to an IPO is a long and arduous journey. For healthcare startups, the pursuit of technological breakthroughs runs parallel to challenges across nearly every dimension of the business — corporate strategy, commercial model, capital operations, and day-to-day management.
Into the Dalton Venture Family | Leveraging Two Technology Platforms — Low-Temperature Plasma and Radiofrequency Ablation — Favamed Charts a Platform Strategy
As of today, Fangrun Medical and its subsidiaries have secured 19 NMPA registrations. Its products are now used in over 1,200 hospitals across China, with successful exports to Europe and Southeast Asia, serving more than 100,000 patients annually.
Survival of the Fittest | Dalton Venture 2022 Annual Partners Meeting (Part One)
Xiangxin — it's both "sunflower" + "heart," and the idea that following your inner passion lets you always grow toward the sun.
We Analyzed 1,000 LP Commitments and Found 30 Hidden Top Family Offices
They are also a microcosm of China's commercial evolution.
The Essential GP Skillset Today: Reading Policy, Reading the Macro Trend, and Getting the Timing Right | Dalton Insight
China's past economic growth was bought with high-intensity input of production factors. The only way to break through going forward is to use technology to transform production relations and shift toward high-quality development.
